QIAGEN OmicSoft and Biomedical Knowledge Base
Drug treatment, toxicology and target safety assessment using QIAGEN Ingenuity Pathway Analysis (IPA) and QIAGEN Omicsoft - Oct 26 2021
384 views
Using public data from GTEx (normal tissue), GEO, cancer collections and more, attendees will learn how to use Omicsoft Lands to:
• Investigate a drug target or biomarker expression across different normal tissues, disease conditions, treatments and more
• Correlate expression of 2 or more genes
• Identify a list of genes or biomarkers specific to treatment, disease, normal tissue, cell type and more
Using findings from peer-reviewed publications and other sources, attendees will learn how to use QIAGEN IPA to:
• Investigate the impact of targeting a gene/protein on different toxicological and biological functions
• Derive tox findings for a gene of interest from QIAGEN IPA’s knowledgebase
• Identify and study toxicity-related pathways, regulators and functions for an internal dataset or a public dataset
• Compare different drug treatments, other conditions or multi-omics data for novel discoveries
Related videos
QIAGEN OmicSoft and Biomedical Knowledge Base
Novel discoveries from public single-cell RNA-seq data using QIAGEN OmicSoft and QIAGEN...
QIAGEN OmicSoft Lands and QIAGEN Ingenuity Pathway Analysis (IPA) provide a...
QIAGEN OmicSoft and Biomedical Knowledge Base
Transcriptomics, Proteomics and Metabolic Changes in Post-Natal Mouse Heart analyzed with...
In the full talk, Jean-Noël Billaud, Ph.D. Senior Principal Scientist,...
QIAGEN OmicSoft and Biomedical Knowledge Base
Checkpoint inhibitors in the context of biomarkers, drug targets and pathways
In this training, we will focus on how you can use QIAGEN Omicsoft Studio and...
QIAGEN OmicSoft and Biomedical Knowledge Base
‘Omics data queries made simple - introducing the QIAGEN OmicSoft API
Do you struggle with finding relevant 'omics datasets for your drug discovery...